Bio­Mo­tiv, Bris­tol-My­ers al­liance bears fruit with new com­pa­ny: An­teros Phar­ma

As a phar­ma­ceu­ti­cal ac­cel­er­a­tor that se­lects and in­cu­bates nascent tech­nol­o­gy from the halls of acad­e­mia, Bio­Mo­tiv is con­stant­ly in need of fund­ing. En­ter Bris­tol-My­ers Squibb — who along with as­sim­i­lat­ing the ar­se­nal of Cel­gene as­sets it ac­quired with the $74 bil­lion ac­qui­si­tion of the big biotech com­pa­ny — is look­ing for fresh meat to bulk up its pipeline.

On Tues­day, Bio­Mo­tiv and Bris­tol-My­ers un­veiled the first com­pa­ny borne out of their 2019 pact: An­teros Phar­ma­ceu­ti­cals, which is fo­cused on dif­fi­cult-to-treat fi­brot­ic and oth­er in­flam­ma­to­ry dis­eases, us­ing tech­nol­o­gy in-li­censed from Yale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER